Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial

Tianqing Chu; Jun Lu; Minghong Bi; Helong Zhang; Wu Zhuang; Yan Yu; Jianhua Shi; Zhendong Chen; Xiaochun Zhang; Qisen Guo; Quan Liu; Huijuan Wu; Jian Fang; Yi Hu; Xiuwen Wang; Cuicui Han; Kai Li; Baohui Han

doi:10.20892/j.issn.2095-3941.2020.0212

Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial

Cancer Biology and Medicine ◽

10.20892/j.issn.2095-3941.2020.0212 ◽

2021 ◽

Vol 18 (3) ◽

pp. 816-824

Author(s):

Tianqing Chu ◽

Jun Lu ◽

Minghong Bi ◽

Helong Zhang ◽

Wu Zhuang ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trial ◽

Small Cell ◽

Efficacy Study ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Lung Cancer Patients ◽

Double Blind Clinical Trial ◽

Equivalent Efficacy

Download Full-text

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

Lung Cancer ◽

10.1016/j.lungcan.2016.01.007 ◽

2016 ◽

Vol 93 ◽

pp. 95-103 ◽

Cited By ~ 28

Author(s):

Maurice Pérol ◽

Tudor-Eliade Ciuleanu ◽

Oscar Arrieta ◽

Kumar Prabhash ◽

Konstantinos N. Syrigos ◽

...

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Clinical Trial ◽

Cancer Patients ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Lung Cancer Patients ◽

Platinum Based Chemotherapy

Download Full-text

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00650-1 ◽

2022 ◽

Author(s):

Caicun Zhou ◽

Ziping Wang ◽

Yuping Sun ◽

Lejie Cao ◽

Zhiyong Ma ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Platinum Based Chemotherapy ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718451079.793497341 ◽

2014 ◽

Author(s):

Laurie Carr

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Disease Progression ◽

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Download Full-text

Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(17)30759-3 ◽

2017 ◽

Vol 18 ◽

pp. S3 ◽

Cited By ~ 11

Author(s):

Baohui Han ◽

Kai Li ◽

Qiming Wang ◽

Yizhuo Zhao ◽

Li Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Third Line ◽

Third Line Treatment

Download Full-text

O-161 Efficacy of antibacterial prophylaxis following myelosuppressive chemotherapy: Results from a randomised, double-blind, placebo-controlled trial of levofloxacin including 220 small cell lung cancer patients

Lung Cancer ◽

10.1016/s0169-5002(05)80295-8 ◽

2005 ◽

Vol 49 ◽

pp. S55

Author(s):

L. Billingham ◽

M. Cullen ◽

N. Steven ◽

C. Gaunt ◽

M. Hastings

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Controlled Trial ◽

Small Cell ◽

Antibacterial Prophylaxis ◽

Small Cell Lung ◽

Double Blind ◽

Myelosuppressive Chemotherapy ◽

Double Blind Placebo ◽

Lung Cancer Patients

Download Full-text

PD6-3-6: A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283344.69129.a5 ◽

2007 ◽

Vol 2 (8) ◽

pp. S433-S434 ◽

Cited By ~ 2

Author(s):

Robert Pirker ◽

Rodryg Ramlau ◽

Wolfgang Schuette ◽

Petr Zatloukal ◽

Irene Ferreira ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Darbepoetin Alfa ◽

Small Cell ◽

Controlled Study ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Extensive Stage

Download Full-text

195TiP A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30468-4 ◽

2018 ◽

Vol 13 (4) ◽

pp. S116-S117

Author(s):

L. Paz-Ares ◽

S. Rubin ◽

Y. Zhao ◽

L. Xu ◽

A. Samkari ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Double Blind Study ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70510-2 ◽

2014 ◽

Vol 15 (1) ◽

pp. 59-68 ◽

Cited By ~ 259

Author(s):

Charles Butts ◽

Mark A Socinski ◽

Paul L Mitchell ◽

Nick Thatcher ◽

Libor Havel ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Stage Iii ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind

Download Full-text

Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data

Cancer Biology and Medicine ◽

10.20892/j.issn.2095-3941.2018.0474 ◽

2019 ◽

Vol 16 (2) ◽

pp. 341

Author(s):

M. Hopkins Ashley ◽

Shahnam Adel ◽

Zhang Sasha ◽

S. Karapetis Chris ◽

Rowland Andrew ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trial ◽

Prognostic Model ◽

Clinical Trial Data ◽

Pooled Analysis ◽

Small Cell ◽

Trial Data ◽

Survival Outcomes ◽

Small Cell Lung ◽

Lung Cancer Patients

Download Full-text

1787P Effect of anlotinib in advanced small cell lung cancer patients with pleural metastases/pleural effusion: A subgroup analysis from a randomized, double-blind phase II trial (ALTER1202)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1548 ◽

2020 ◽

Vol 31 ◽

pp. S1036

Author(s):

Y. Liu ◽

Y. Cheng ◽

Q. Wang ◽

K. Li ◽

J. Shi ◽

...

Keyword(s):

Lung Cancer ◽

Pleural Effusion ◽

Cancer Patients ◽

Subgroup Analysis ◽

Phase Ii Trial ◽

Small Cell ◽

Small Cell Lung ◽

Double Blind ◽

Lung Cancer Patients ◽

Pleural Metastases

Download Full-text